{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-258568","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.782811+00:00","generated_at":"2026-05-17T01:13:57.032284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances","bullets":["Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.","Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).","First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.","Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.","Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-258568","json":"https://secwatch.observer/filing/0001193125-25-258568.json","markdown":"https://secwatch.observer/filing/0001193125-25-258568.md","text":"https://secwatch.observer/filing/0001193125-25-258568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/0001193125-25-258568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/pstv-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:13:57.032284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}